Turmeric as Treatment in Epilepsy

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03254680

Enrollment

Registered

2017-08-18

Start date

2018-03-31

Completion date

2018-11-30

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, Focal Seizures

Keywords

Turmeric Oil, antiseizure medications, ar-turmerone

Brief summary

This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures. Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months. Patients and caregivers will be asked to keep a seizure diary logging all clinical events during the course of the study. Serum comprehensive metabolic panel, complete blood count with differential, and antiseizure medication levels, will be monitored at baseline, 1.5 months, and at the end of 3 months.

Interventions

DIETARY_SUPPLEMENTTurmeric

Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with greater than greater than six seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures followed at NYU CEC.

Exclusion criteria

* Patients expected to have changes to any medications or supplements during study period * exposure to any investigational agent in the month prior to study entry * pregnant or breast feeding women, positive pregnancy test * history of non-compliance * known drug or alcohol dependence * known baseline hematologic * liver function * renal function * absorption * absorption

Design outcomes

Primary

Measure	Time frame	Description
Number of epilepsy patients enrolled in study	3 months	feasibility of recruiting patients into a prospective study designed to evaluate the effect of orally ingested turmeric oil on seizures.

Secondary

Measure	Time frame
Number of epilepsy seizures post epilepsy treatment with turmeric	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026